We’re constantly on the lookout for game-changing science
Our focus is transformation – building tomorrow’s healthcare, with partners striving to bring innovation to patients worldwide.
Venture capital investment in early-stage companies
Sanofi Ventures invests in early-stage biotech and digital health companies of strategic interest. We offer our portfolio companies select access to expertise and capabilities, supporting our shared goal to improve the lives of patients.
Business Development: win–win partnership
We’re all about flexibility. With a broad range and global scope, our Business Development team can fully support the strategic intent of any partnership. Whether it’s in-and-out licensing, collaborative R&D, joint ventures, or strategic alliances, we’re eager to collaborate with our partners to bring innovative science to patients.
For more information, contact our Business Development Team
Every relationship is unique. That’s why it’s so important to have a central point of contact who can ensure a smooth, effective transition from signature to execution. Our Alliance Management team keeps you connected, and ensures our partnered assets are developed and commercialized as agreed.
Partnering 2022 in a few figures
Our process ensures that our partnering teams are committed to evaluating your business proposal carefully and in a timely manner, ensuring seamless collaboration at all stages.
Why partner with us?
- We bring the right people together and ensure they have the tools to pursue first-in-class science.
- We take a direct, straightforward approach to communication and solve problems together.
- Our senior leaders are accessible and engaged , bringing clarity and alignment.
- We build long-lasting, mutually beneficial relationships that drive growth.
What our partners say
“Building on the success of our existing collaboration on hematologic targets, we are pleased to expand and strengthen our partnership with Sanofi on NK Cell Engagers with the addition of up to three new programs, including in solid tumors. Sanofi’s investment in Innate further validates the value of our ANKETTM platform and its potential to address multiple tumor types. By incorporating various tumor antigen binders, NK Cell Engagers are a versatile technology that may provide new options for patients and offer clinical benefit across multiple cancers, whilst also maintaining a good safety profile.”
Yannis Morel, PH.D., Executive Vice President, Product Portfolio Strategy & Business Development
“Sanofi is a global leader in the development and commercialization of innovative therapies, and we look forward to working with their talented team to build novel small molecule therapeutics that modify RNA splicing for the treatment of critical diseases of high unmet need. We are excited to develop drugs for challenging targets with Sanofi and look forward to working together on these potential first- and best-in-class programs.”
Bill Haney, Chief Executive Officer
“We are thrilled to enter our first major licensing transaction with a partner of Sanofi’s caliber and capabilities as a global leader in the development and commercialization of rare disease therapies. Our goal since initiating this program has been to develop a treatement to allow FSHD patients to live a normal life. The philosophy driving our DREAmiR discovery platform focuses on patient centered drug development and strong scientific decision making. We believe Sanofi shares these core values on creating life changing therapies, making this an ideal partnership to bring forward our anti-DUX4 RNA therapy.”
Anthony Saleh, Founder and Chief Executive Offier